359 related articles for article (PubMed ID: 8459055)
21. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor.
Xiao Z; Théroux P
Circulation; 1998 Jan; 97(3):251-6. PubMed ID: 9462526
[TBL] [Abstract][Full Text] [Related]
22. Effects of aspirin DL-lysine on thrombin generation in unstable angina pectoris.
Yasu T; Oshima S; Imanishi M; Nonogi H; Haze K; Kuramochi M; Omae T; Hayashi Y; Yamamoto S
Am J Cardiol; 1993 May; 71(13):1164-8. PubMed ID: 8480641
[TBL] [Abstract][Full Text] [Related]
23. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
[TBL] [Abstract][Full Text] [Related]
24. Fibrinopeptide A excretion in urine: a marker of the cumulative thrombin activity in stable versus unstable angina patients.
Ardissino D; Gamba MG; Merlini PA; Rolla A; Barberis P; Demicheli G; Testa S; Bruno N; Specchia G
Am J Cardiol; 1991 Sep; 68(7):58B-63B. PubMed ID: 1892068
[TBL] [Abstract][Full Text] [Related]
25. Antithrombotic activity of argatroban in experimental thrombosis in the rabbit.
Berry CN; Girard D; Girardot C; Lochot S; Lunven C; Visconte C
Semin Thromb Hemost; 1996; 22(3):233-41. PubMed ID: 8836007
[TBL] [Abstract][Full Text] [Related]
26. Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential.
Becker RC; Spencer FA; Li Y; Ball SP; Ma Y; Hurley T; Hebert J
J Am Coll Cardiol; 1999 Oct; 34(4):1020-7. PubMed ID: 10520784
[TBL] [Abstract][Full Text] [Related]
27. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.
Guy S; Kitchen S; Maclean R; Van Veen JJ
Int J Lab Hematol; 2015 Dec; 37(6):834-43. PubMed ID: 26305560
[TBL] [Abstract][Full Text] [Related]
28. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase.
Galvani M; Abendschein DR; Ferrini D; Ottani F; Rusticali F; Eisenberg PR
J Am Coll Cardiol; 1994 Nov; 24(6):1445-52. PubMed ID: 7930274
[TBL] [Abstract][Full Text] [Related]
29. Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin.
Bijsterveld NR; Moons AH; Meijers JC; Tijssen JG; Büller HR; Levi M; Peters RJ
J Am Coll Cardiol; 2002 Mar; 39(5):811-7. PubMed ID: 11869846
[TBL] [Abstract][Full Text] [Related]
30. Antithrombotic treatment (argatroban vs. heparin) in coronary angioplasty in angina pectoris: effects on inflammatory, hemostatic, and endothelium-derived parameters.
Suzuki S; Matsuo T; Kobayashi H; Matsuo M; Shimamo C; Koide M; Sakamoto S
Thromb Res; 2000 May; 98(4):269-79. PubMed ID: 10822073
[TBL] [Abstract][Full Text] [Related]
31. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
Berry CN; Girard D; Lochot S; Lecoffre C
Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274
[TBL] [Abstract][Full Text] [Related]
32. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.
Becker RC; Cannon CP; Tracy RP; Thompson B; Bovill EG; Desvigne-Nickens P; Randall AM; Knatternud G; Braunwald E
Am Heart J; 1996 Mar; 131(3):421-33. PubMed ID: 8604620
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous use of argatroban and heparin during cardiopulmonary bypass.
Okamura T; Shin'oka T; Ishibashi N; Ishii H; Kurosawa H
Asian Cardiovasc Thorac Ann; 2010 Feb; 18(1):22-6. PubMed ID: 20124292
[TBL] [Abstract][Full Text] [Related]
34. [Experimental and clinical results with the thrombin inhibitor Argatroban].
Breddin HK
Hamostaseologie; 2002 Aug; 22(3):55-9. PubMed ID: 12215762
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Pehrsson S; Johansson K; Kjaer M; Elg M
Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
[TBL] [Abstract][Full Text] [Related]
36. Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study.
Rössig L; Genth-Zotz S; Rau M; Heyndrickx GR; Schneider T; Gulba DC; Desaga M; Buerke M; Harder S; Zeiher AM;
Int J Cardiol; 2011 Apr; 148(2):214-9. PubMed ID: 20226548
[TBL] [Abstract][Full Text] [Related]
37. Determinants of rebound thrombin activity after cessation of heparin in patients undergoing coronary interventions.
Watkins MW; Luetmer PA; Schneider DJ; Witmer WT; Vaitkus PT; Sobel BE
Cathet Cardiovasc Diagn; 1998 Jul; 44(3):257-64. PubMed ID: 9676792
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory effect of argatroban on thrombin-antithrombin III complex after percutaneous transluminal coronary angioplasty.
Sakamoto S; Hirase T; Suzuki S; Tsukamoto T; Miki T; Yamada T; Matsuo T
Thromb Haemost; 1995 Aug; 74(2):801-2. PubMed ID: 8585029
[No Abstract] [Full Text] [Related]
39. Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters.
Akimoto K; Klinkhardt U; Zeiher A; Niethammer M; Harder S
J Clin Pharmacol; 2011 Jun; 51(6):805-18. PubMed ID: 20663996
[TBL] [Abstract][Full Text] [Related]
40. [Antithrombin therapy in acute coronary syndromes].
Maseri A; Andreotti F; Biasucci LM; Rebuzzi AG
Cardiologia; 1994 Dec; 39(12 Suppl 1):7-13. PubMed ID: 7634317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
